Clinical Trials Actively Recruiting Patients With Renal Cell Carcinoma

Get Permission

The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on immunotherapy as treatment for renal cell carcinoma. These studies are researching combination chemotherapies; immunotherapies; radiosurgery techniques; stereotactic body radiation therapy; contrast screening for recurrence; and more. All of the studies are listed on the National Institutes of Health website at

Phase I/II

Study Title: Phase I/II Trial of Vandetanib in Combination With Metformin in Subjects With Hereditary Leiomyomatosis and Renal Cell Carcinoma or Succinate Dehydrogenase–Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

Study Type: Phase I/II/interventional/parallel assignment

Study Sponsor and Collaborators: National Cancer Institute, National Institutes of Health Clinical Center

Purpose: To test the combination of metformin and vandetanib in people with advanced kidney cancer. Phase I of the study will determine a safe dose for the drugs. Phase II will test this dose in people with certain kidney cancers.

Primary Outcome Measures: Phase 1 component: To establish the safety and maximum tolerated dose of vandetanib and metformin when used in combination in patients with metastatic renal cell carcinoma [time frame: 1–2 years]. Phase 2 component: To determine the overall response rate (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) following treatment with the combination of vandetanib and metformin in patients with (1) advanced renal cell carcinoma associated with hereditary leiomyomatosis or succinate dehydrogenase–associated kidney cancer and (2) advanced sporadic/non–hereditary leiomyomatosis and papillary renal cell carcinoma [time frame: 2–3 years]

Principal Investigator: Ramaprasad Srinivasan, MD, National Cancer Institute; contact Martha Ninos, RN, (301) 496-6353, Identifier: NCT02495103

Study Title: Phase I/II Study of Ixazomib With Pegylated Interferon-alpha 2b in Metastatic Renal Cell Carcinoma

Study Type: Phase I/II/interventional/single-group sssignment

Study Sponsor and Collaborators: Fox Chase Cancer Center

Purpose: To test the combination of pegylated interferon-alpha 2b with ixazomib in metastatic renal cell carcinoma. Researchers believe that by disabling the protein complex nuclear factor kB (NF-kB), which controls the transfer of genetic information, and using ixazomib, they can promote necrotic cell death of renal cell carcinoma using interferon alpha-2b.

Primary Outcome Measures: Nonhematologic toxicity ≥ grade 3 per Common Terminology Criteria for Adverse Events (CTCAE) v4 except: [time frame: up to week 8]

Principal Investigator: Daniel Geynisman, MD, Fox Chase Cancer Center; (215) 728-4300, Identifier: NCT02447887

Phase II

Study Title: A Phase II Study of CyberKnife Radiosurgery for Renal Cell Carcinoma

Study Type: Phase II/interventional/single-group assignment

Study Sponsor and Collaborators: Beth Israel Deaconess Medical Center

Purpose: CyberKnife-based radiosurgery is a way to deliver large doses of radiation accurately to a tumor. The purpose of this protocol is to evaluate the role of radiosurgery for the treatment of clinically localized primary renal cell carcinoma.

Primary Outcome Measures: To determine the freedom from local tumor progression in patients treated with CyberKnife radiosurgery for primary renal tumors at 6 months [time frame: 2 years]

Principal Investigator: Irving D. Kaplan, MD, Beth Israel Deaconess Medical Center; (617) 667-2345, Identifier: NCT01890590

Study Title: A Phase II Randomized Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for the Treatment of Localized Renal Cell Carcinoma

Study Type: Phase II/interventional/parallel assignment

Study Sponsor and Collaborators: University of Michigan Cancer Center

Purpose: To assess whether stereotactic body radiation therapy can provide comparable local control, with similar or improved toxicity rates compared with radiofrequency ablation when treating small renal cell carcinomas.

Primary Outcome Measures: Proportion of patients with local control of disease [time frame: 12 months]; cumulative incidence of grade 2 and greater toxicities [time frame: up to 30 days after the last study treatment]

Principal Investigator: Daniel Spratt, MD, University of Michigan Cancer Center; (734) 936-4300, Identifier: NCT02138578

Study Title: Two- and Three-Dimensional Contrast-Enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation

Study Type: Phase II/interventional/single-group assignment

Study Sponsor and Collaborators: Thomas Jefferson University

Purpose: To determine whether contrast-enhanced ultrasound can be used to assess the recurrence of renal cell carcinoma after cryoablation compared with contrast-enhanced computed tomography or magnetic resonance (the standard evaluation)

Primary Outcome Measures: Identification of renal cell carcinoma recurrence [time frame: day of study]

Principal Investigator: John R. Eisenbrey, PhD, Thomas Jefferson University; (215) 503-5188, Identifier: NCT02440334

Study Title: A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid ­Features

Study Type: Phase II/interventional

Study Sponsor and Collaborators: Eastern Cooperative Oncology Group, National Cancer Institute

Purpose: To study the combination of sunitinib malate together with or without gemcitabine hydrochloride to see how well they work in treating patients with advanced unresectable kidney cancer

Primary Outcome Measures: Response rate

Principal Investigator: Naomi S. Balzer-Haas, MD, Abramson Cancer Center of the University of Pennsylvania; reference for all 99 study locations and contact information Identifier: NCT01164228 ■

Editor’s Note: The clinical trials presented here do not represent all the trials listed on For the complete list, go to